Skip to main content

Table 3 Difference in clinicopathological features due to body mass index categorized in TNBC

From: Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy

hba

Body mass index (kg/m2)

p value

Body mass index (kg/m2

p value

Body mass index (kg/m2)

p value

≤ 18.5

(n = 17)

>  18.5

(n = 109)

≤ 25

(n = 98)

>  25

(n = 28)

≤ 30

(n = 123)

>  30

(n = 3)

Age (years old)

0.258

  ≤ 60

11 (64.7%)

78 (71.6%)

 

67 (68.4%)

22 (78.6%)

 

86 (69.9%)

3 (100.0%)

  > 60

6 (35.3%)

31 (28.4%)

0.564

31 (31.6%)

6 (21.4%)

0.296

37 (30.1%)

0 (0.0%)

Tumor size (mm)

0.433

  ≤ 20.0

4 (23.5%)

17 (15.6%)

 

18 (18.4%)

3 (10.7%)

 

20 (16.3%)

1 (33.3%)

  > 20.0

13 (76.5%)

92 (84.4%)

0.414

80 (81.6%)

25 (89.3%)

0.338

103 (83.7%)

2 (66.7%)

Skin infiltration

0.519

 Negative

13 (76.5%)

98 (89.9%)

 

88 (89.8%)

23 (82.1%)

 

108 (87.8%)

3 (100.0%)

 Positive

4 (23.5%)

11 (10.1%)

0.112

10 (10.2%)

5 (17.9%)

0.270

15 (12.2%)

0 (0.0%)

Lymph node status

0.952

 Negative

4 (23.5%)

36 (33.0%)

 

32 (32.7%)

8 (28.6%)

 

39 (31.7%)

1 (33.3%)

 Positive

13 (76.5%)

73 (67.0%)

0.434

66 (67.3%)

20 (71.4%)

0.682

84 (68.3%)

2 (66.7%)

Ki67

0.695

  ≤ 14%

2 (11.8%)

28 (25.7%)

 

24 (24.5%)

6 (21.4%)

 

29 (23.6%)

1 (33.3%)

  > 14%

15 (88.2%)

81 (74.3%)

0.210

74 (75.5%)

22 (78.6%)

0.737

94 (76.4%)

2 (66.7%)

Objective response rate

0.504

 Non-Responders

6 (35.3%)

10 (9.2%)

 

14 (14.3%)

2 (7.1%)

 

16 (13.0%)

0 (0.0%)

 Responders

11 (64.7%)

99 (90.8%)

0.003

84 (85.7%)

26 (92.9%)

0.317

107 (87.0%)

3 (100.0%)

Pathological response

0.777

 Non-pCR

9 (52.9%)

65 (59.6%)

 

58 (59.2%)

16 (57.1%)

 

72 (58.5%)

2 (66.7%)

 pCR

8 (47.1%)

44 (40.4%)

0.602

40 (40.8%)

12 (42.9%)

0.847

51 (41.5%)

1 (33.3%)

TILs

0.100

 Low

12 (70.6%)

47 (43.1%)

 

50 (51.0%)

9 (32.1%)

 

59 (48.0%)

0 (73.7%)

 High

5 (29.4%)

62 (56.9%)

0.035

48 (49.0%)

19 (67.9%)

0.077

64 (52.0%)

3 (100.0%)

  1. TNBC triple negative breast cancer, pCR pathological complete response, TILs tumor-infiltrating lymphocytes